Inventiva S.A. (ENXTPA: IVA)
Health Care · Biotechnology · FR
€3.15
+10.54% today · -37.7% 1Y
Inventiva S.A. (ENXTPA: IVA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $836.35M and employs 73 people.
Over the last twelve months the share price has lost 37.7%, trading between 2.73 and 6.20.
Tweenvest scores Inventiva S.A. across four factors: quality 31/100, value 45/100, growth 23/100. Its strongest factor is value.
IVA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $836.35M
- Revenue (TTM)
- $2.81M
- P/E
- —
- EPS
- -0.92
- Dividend yield
- —
- Beta (5Y)
- 1.00
- 52-week high
- €6.20
- 52-week low
- €2.73
- Avg volume (3M)
- —
- Shares outstanding
- 236.28M
- Employees
- 73
- Next earnings
- —
About Inventiva S.A.
Inventiva S.A. is a biopharmaceutical firm currently in the clinical development phase, specializing in creating orally administered small molecule treatments for conditions such as non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and various other ailments. Their primary drug candidate, Lanifibranor, has successfully concluded Phase IIb clinical trials for the management of NASH. Furthermore, the company is advancing Odiparcil, a compound that has finished Phase IIa clinical testing specifically for treating the MPS VI subtype. Beyond these, Inventiva maintains a development pipeline featuring several early-stage projects targeting oncology and other medical conditions. Strategic partnerships are in place with AbbVie to address autoimmune diseases, and with Boehringer Ingelheim International GmbH for innovating therapies for idiopathic pulmonary fibrosis. Established in 2011, Inventiva S.A. operates from its headquarters in Daix, France.
- ISIN
- FR0013233012
- Founded
- 2011
- Listed since
- Feb 15, 2017
- Exchange
- Euronext Paris
- Currency
- EUR
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Oxford Biomedica plcLSE: OXB | $871.14M | £5.28 | -2.94% |
| Monte Rosa Therapeutics, Inc.NasdaqGS: GLUE | $867.64M | $10.17 | +3.04% |
| PeptiDream Inc.TSE: 4587 | $862.11M | ¥1,060.50 | +0.19% |
| Arbutus Biopharma CorporationNasdaqGS: ABUS | $848.77M | $4.29 | -4.24% |
| Sana Biotechnology, Inc.NasdaqGS: SANA | $814.26M | $2.72 | -1.09% |
| Ardelyx, Inc.NasdaqGM: ARDX | $812.35M | $3.26 | -1.51% |
| Immix Biopharma, Inc.NasdaqCM: IMMX | $802.50M | $9.49 | -1.96% |
| Candel Therapeutics, Inc.NasdaqGM: CADL | $778.96M | $9.82 | -3.54% |
Figures last refreshed Oct 4, 2026.